Home › Funds › Nantahala Capital Management, LLC › VOR
Nantahala Capital Management, LLC position in VOR
VOR BIOPHARMA INC · Health Care
Nantahala Capital Management, LLC reported holding 931,644 shares of VOR (VOR BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$17.8M, representing 0.82% of its reported portfolio and ranking #42 among its reported holdings. Nantahala Capital Management, LLC has disclosed VOR holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Nantahala Capital Management, LLC's VOR position evolved
Nantahala Capital Management, LLC first disclosed a stake in VOR in Q2 2026 at 845,000 shares (US$15.6M). The position peaked in Q3 2026 at 931,644 shares, worth US$17.8M. Across 2 filings, Nantahala Capital Management, LLC increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 931,644 shares valued at US$17.8M — an increase of 86,644 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 845.00K | $15.56M | New |
| Q3 2026 | 931.64K | $17.78M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About VOR and 13F data
VOR (VOR BIOPHARMA INC) is a Health Care company. 74 other funds we track also report a position in VOR — the largest reported positions include TCG Crossover Management, LLC (US$104.4M), FCPM III SERVICES B.V. (US$75.8M), Venrock Adviser, LLC (US$56.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding VOR
- TCG Crossover Management, LLC 5.67M sh · $104.44M · Q2 2026
- FCPM III SERVICES B.V. 4.12M sh · $75.80M · Q2 2026
- Venrock Adviser, LLC 3.04M sh · $56.00M · Q2 2026
- Frazier Life Sciences Management, L.P. 2.54M sh · $46.83M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 2.40M sh · $44.22M · Q2 2026
- Caligan Partners LP 1.93M sh · $35.44M · Q2 2026
- Paradigm Biocapital Advisors LP 1.75M sh · $32.22M · Q2 2026
- GREAT POINT PARTNERS LLC 1.70M sh · $31.30M · Q2 2026
- NAN FUNG TRINITY (HK) Ltd 721.55K sh · $13.77M · Q3 2026
- ADAR1 Capital Management, LLC 680.63K sh · $12.53M · Q2 2026
- Logos Global Management LP 650.00K sh · $11.97M · Q2 2026
- Rosalind Advisors, Inc. 648.60K sh · $11.94M · Q2 2026
More on Nantahala Capital Management, LLC
FAQ
How long has Nantahala Capital Management, LLC held VOR?
Nantahala Capital Management, LLC has disclosed VOR holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Nantahala Capital Management, LLC's current position in VOR?
As of Q3 2026, Nantahala Capital Management, LLC holds 931.64K shares of VOR (VOR BIOPHARMA INC), valued at $17.78M, representing 0.82% of its reported portfolio and ranking #42.
Has Nantahala Capital Management, LLC been buying or selling VOR?
In the latest 13F filing (Q3 2026), Nantahala Capital Management, LLC increased its position in VOR. The position peaked in Q3 2026 at 931.64K shares.
Which other funds hold VOR?
Other major institutional holders of VOR include TCG Crossover Management, LLC, FCPM III SERVICES B.V., Venrock Adviser, LLC, among 74 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.